Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021

Simple item page
dc.contributor.authorZambrano, Laura D.
dc.contributor.authorNewhams, Margaret M.
dc.contributor.authorOlson, Samantha M.
dc.contributor.authorHalasa, Natasha B.
dc.contributor.authorPrice, Ashley M.
dc.contributor.authorBoom, Julie A.
dc.contributor.authorSahni, Leila C.
dc.contributor.authorKamidani, Satoshi
dc.contributor.authorTarquinio, Keiko M.
dc.contributor.authorMaddux, Aline B.
dc.contributor.authorHeidemann, Sabrina M.
dc.contributor.authorBhumbra, Samina S.
dc.contributor.authorBline, Katherine E.
dc.contributor.authorNofziger, Ryan A.
dc.contributor.authorHobbs, Charlotte V.
dc.contributor.authorBradford, Tamara T.
dc.contributor.authorCvijanovich , Natalie Z.
dc.contributor.authorIrby, Katherine
dc.contributor.authorMack, Elizabeth H.
dc.contributor.authorCullimore, Melissa L.
dc.contributor.authorPannaraj, Pia S.
dc.contributor.authorKong, Michele
dc.contributor.authorWalker, Tracie C.
dc.contributor.authorGertz, Shira J.
dc.contributor.authorMichelson, Kelly N.
dc.contributor.authorCameron, Melissa A.
dc.contributor.authorChiotos, Kathleen
dc.contributor.authorMaamari, Mia
dc.contributor.authorSchuster, Jennifer E.
dc.contributor.authorOrzel, Amber O.
dc.contributor.authorPatel, Manish M.
dc.contributor.authorCampbell, Angela P.
dc.contributor.authorRandolph, Adrienne G.
dc.contributor.authorOvercoming COVID-19 Investigators
dc.contributor.departmentPediatrics, School of Medicine
dc.date.accessioned2024-06-21T15:54:08Z
dc.date.available2024-06-21T15:54:08Z
dc.date.issued2022-01-14
dc.eprint.versionFinal published version
dc.identifier.citationZambrano, L. D. (2022). Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years—United States, July–December 2021. MMWR. Morbidity and Mortality Weekly Report, 71. https://doi.org/10.15585/mmwr.mm7102e1
dc.identifier.urihttps://hdl.handle.net/1805/41748
dc.language.isoen_US
dc.publisherU.S. Department of Health & Human Services
dc.relation.isversionof10.15585/mmwr.mm7102e1
dc.relation.journalMorbidity and Mortality Weekly Report
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectmultisystem inflammatory syndrome in children (MIS-C)
dc.subjectSARS-CoV-2
dc.subjectBNT162b2 vaccine
dc.titleEffectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Zambrano2022Effectiveness-PubP.pdf
Size:
146.84 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles